ECO Animal Health Launches Ecovaxxin MS Poultry Vaccine Across European Union

Moving to capture a critical share of the European livestock biologicals market, ECO Animal Health Group Plc. has announced the official commercial rollout of ECOVAXXIN® MS across the European Union.

The launch represents a major commercial milestone for the UK-headquartered animal health innovator, marking the first fully developed vaccine from its proprietary internal research and development pipeline to successfully transition into commercial market entry.

To maximise day-one market penetration, the group is leveraging its established commercial infrastructure and distribution networks—originally constructed to support its global flagship antibiotic brand, Aivlosin®. Strategic distribution agreements have been finalised across all primary EU poultry production hubs, granting the company immediate, streamlined access to a poultry birds market representing more than 220 million layer birds annually.

Clinical Impact: Targeted Protection Against Mycoplasma synoviae

ECOVAXXIN MS is a live bacterial vaccine designed for the active immunisation of future layer and breeder chickens from four weeks of age. The product specifically targets Mycoplasma synoviae (MS), a persistent and highly contagious bacterial pathogen that infiltrates the respiratory tract and joint linings of domestic fowl.

By introducing a controlled, stable, and attenuated live strain of the bacteria, the vaccine stimulates a robust local and systemic immune response. Clinical trials submitted for regulatory validation demonstrate that early vaccination achieves the following clinical parameters:

• Suppression of Air-Sacculitis: Minimizes the severity of inflammation and mucous accumulation within the avian air-sac system, reducing secondary opportunistic bacterial infections (such as E. coli septicaemia).

• Reduction of Foot-Pad Lesions: Prevents the bacteria from localizing in the synovial membranes of the joints, significantly lowering the incidence of painful foot-pad lesions, sternal bursitis, and subsequent lameness.

• Preservation of Oviduct Integrity: Safeguards the developing reproductive tracts of young pullets, ensuring long-term systemic stability before the birds transition into their active laying cycles.

Industrial Imperative: Mitigating the 5% to 10% Egg Drop Syndrome

For commercial poultry integrators, sub-clinical Mycoplasma synoviae infections represent a severe economic drain. Unlike acute, high-mortality viral epidemics, MS frequently operates as a stealth infection within dense production sheds, circulating slowly without causing massive, immediate bird mortalities.

However, the chronic systemic inflammation induced by the pathogen directly impacts feed conversion ratios and production efficiency. In laying hens, confirmed MS outbreaks are directly responsible for causing a sharp 5% to 10% reduction in total egg production across affected flocks.

Beyond raw volume deficits, the disease compromises eggshell quality. Affected hens frequently produce thin-shelled, brittle, or misshapen eggs with apical abnormalities, rendering them unfit for commercial transport and packaging, which results in significant downgrade losses at the grading station.

By implementing an automated, flock-wide preventative vaccination protocol at the four-week mark, producers can establish a biological shield over future layer lines, protecting uniform egg output, lowering dependence on therapeutic therapeutic antibiotics, and stabilizing farm-gate profitability.

Global Roadmap: Expanding into Larger US and Asian Hubs

With the European Union rollout established, ECO Animal Health is aggressively advancing its international regulatory strategy to expand the commercial footprint of its vaccine portfolio.

The company is progressing through parallel registration pathways in the United States, Latin America, and high-density Asian poultry markets, where Mycoplasma control remains an expensive operational challenge for corporate integrators.

The strategy is backed by parallel pipeline developments. The company recently secured a favorable safety assessment from the United States Department of Agriculture (USDA) for its sibling pipeline asset, ECOVAXXIN® MG (targeting Mycoplasma gallisepticum), confirming its non-pathogenic stability in both target and non-target avian species.

By broadening its portfolio beyond traditional veterinary pharmaceuticals into targeted, preventative biologicals, ECO Animal Health is positioning itself to address the growing global regulatory and retail demand for sustainable animal protein production and reduced reliance on shared-class antibiotics.